Literature DB >> 2188662

Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection.

M S Meltzer1, D R Skillman, P J Gomatos, D C Kalter, H E Gendelman.   

Abstract

We have presented evidence in this review for the following: (a) Macrophages are likely the first cell infected by HIV. Recovery of HIV from macrophages has been documented in the early stages of infection in which virus isolation in T cells is unsuccessful and detectable levels of antibodies against HIV are absent. (b) Macrophages are major reservoirs for HIV during all stages of infection. Unlike the lytic infection of T cells, HIV-infected macrophages show little or no virus-induced cytopathic effects. HIV-infected macrophages persist in tissue for extended periods of time (months) with large numbers of infectious particles contained within intracytoplasmic vacuoles. (c) Macrophages are a vector for the spread of infection to different tissues within the patient and between individuals. Several studies suggest a "Trojan horse" role for HIV-infected macrophages in the dissemination of infectious particles. The predominant cell in most bodily fluids (alveolar fluid, colostrum, semen, vaginal secretions) is the macrophage. In semen, for example, the numbers of macrophages exceed those of lymphocytes by more than 20-fold. (d) Macrophages are major regulatory cells that control the pace and intensity of disease progression in HIV infection. Macrophage secretory products are implicated in the pathogenesis of CNS disease and in control of viral latency in HIV-infected T cells. This litany of events in which macrophages participate in HIV-infection in humans parallels similar observations in such animal lentivirus infections as visna-maedi or caprine arthritis-encephalitis viruses. HIV interacts with monocytes differently than with T cells. Understanding this interaction may more clearly define both the pathogenesis of HIV disease and strategies for therapeutic intervention.

Entities:  

Mesh:

Year:  1990        PMID: 2188662     DOI: 10.1146/annurev.iy.08.040190.001125

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  85 in total

1.  The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.

Authors:  E C Darcissac; M J Truong; J Dewulf; Y Mouton; A Capron; G M Bahr
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy.

Authors:  Tracy Fischer-Smith; Sidney Croul; Aderonke Adeniyi; Katarzyna Rybicka; Susan Morgello; Kamel Khalili; Jay Rappaport
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

Review 3.  Debate: "is increasing neuroinflammation beneficial for neural repair?".

Authors:  Keith A Crutcher; Howard E Gendelman; Jonathan Kipnis; J Regino Perez-Polo; V H Perry; Phillip G Popovich; Lynne C Weaver
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-23       Impact factor: 4.147

4.  Effect of IFN-gamma on the proliferation of Toxoplasma gondii in monocytes and monocyte-derived macrophages from AIDS patients.

Authors:  F G Delemarre; A Stevenhagen; F P Kroon; M Y van Eer; P L Meenhorst; R van Furth
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

5.  Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani.

Authors:  R Bernier; S J Turco; M Olivier; M Tremblay
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l.

Authors:  J J Lum; A A Pilon; J Sanchez-Dardon; B N Phenix; J E Kim; J Mihowich; K Jamison; N Hawley-Foss; D H Lynch; A D Badley
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Alveolar macrophages from subjects infected with HIV-1 express macrophage inflammatory protein-1 alpha (MIP-1 alpha): contribution to the CD8+ alveolitis.

Authors:  M Denis; E Ghadirian
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells.

Authors:  A Bergamini; M Capozzi; L Ghibelli; L Dini; A Salanitro; G Milanese; T Wagner; S Beninati; C D Pesce; C Amici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Tissue infiltration in a CD8 lymphocytosis syndrome associated with human immunodeficiency virus-1 infection has the phenotypic appearance of an antigenically driven response.

Authors:  S Itescu; J Dalton; H Z Zhang; R Winchester
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 10.  Overcoming pharmacologic sanctuaries.

Authors:  Theodore J Cory; Timothy W Schacker; Mario Stevenson; Courtney V Fletcher
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.